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Background: Aortic stenosis imposes a chronic pressure overload on the left
ventricle. TAVR leads to an abrupt removal of the mechanical impediment to left
ventricular outﬂow. We examined the immediate hemodynamic changes that occur in
patients with severe aortic stenosis following successful T.A.V.R
Methods: Consecutive patients undergoing T.A.V.R. were eligible for inclusion.
Exclusion criteria were contraindications to pulmonary artery catheterization and
periprocedural complications requiring conversion to surgery. Hemodynamic
measurements were performed in all patients at baseline, and at 6 hours and 24 hours
following the procedure. Pertinent clinical and echocardiographic data were assessed
as well.
Results: Fifty-six patients (54.4% male) with severe aortic stenosis (mean AVA
0.69cm2, mean gradient 48.312mmHg) were included in the study and underwent
TAVR via transfemoral (87.7%) or alternative route (12.3%), with either of the two
commercially available valves Edwards Sapien XT (66.7%) or Medtronic CoreValve
(33.3%), and either under general anesthesia (73.7%) or with conscious sedation
(22.3%).Table 1 summarizes the hemodynamic changes between baseline and 24
hours post procedure.VARIABLE N BASELINE 24HRS p-value
Arterial Pressure-mean
(mmHg)
50 84.616.5 82.310.8 0.298
Diastolic Arterial
Pressure(mmHg)
46 59.913.8 55.110.3 0.018
Heart Rate (/min) 49 63.811.9 78.612.2 0.001
CVP/RA-mean(mmHg) 51 13.05.2 8.83.7 0.001
Pulmonic Pressure-mean
(mmHg)
49 30.78.6 27.27.7 0.004
Wedge Pressure-mean
(mmHg)
49 22.96.7 19.16.6 0.001
Cardiac Output (l/min) 48 3.81.2 5.61.5 0.001
Cardiac Index
(l/min/m2)
46 2.00.5 3.00.7 0.001
Stroke Volume (ml) 32 58.515.5 71.518.2 0.001
Stroke Volume Index (ml/
m2)
32 32.17.7 39.18.8 0.001
SVR (dynes*sec/cm5) 47 1556 491 1062319 0.001
SVRI
(dynes*sec/cm5/m2)
46 2833811 1957513 0.001
PVR (dynes*sec/cm5) 44 168121 11674 0.001
PVRI
(dynes*sec/cm5/m2)
43 302210 207128 0.001
PATIENTS +BAV (96) -BAV (64)
Previous BAV (n) 3 3
Vmax/mean grad/area 4.6/55/ 0.6 4.4/49/0.6
AR> grade 1 (%) 61 52
TAVI
TF/TA/TaO (n) 63/32/1 48/16/0
Valve size (23/26/29) (n) 39/52/5 21/36/7
Postdilatation (n) 10 7
Complications (n) 10 - 5 pericard effus;4 ECC
;1 stuck cusp
7 - 2 TIA;2 peric eff;2
balloon rupt;1 root rupture
1 MONTH f/u
Vmax/mean grad 2.2/11 2.1/10
PVL> grade 1 (n) 25 16
Stroke (n) 6 3
New PPM (n) 2 0
Death (n) 8 4Conclusions: The hemodynamic proﬁle of patients in the immediate post TAVR
period is noted for substantial rise in stroke volume and cardiac output; signiﬁcant
drop in pulmonary and peripheral vascular resistances; and a signiﬁcant decline in the
ventricular ﬁlling pressures. Patients commonly require support with intravenous
ﬂuids and occasionally with vasoconstricting agents during the ﬁrst 24 hours.
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Background: The cost-effectiveness of transfemoral/transapical TAVI vs. medical
management (MM) has been established in a number of studies using data from the
PARTNER B trial. To date no cost-effectiveness analysis has employed prospectiveB218 JACC Vol 62/18/Suppl B j October 27–Novemberdata collected solely for the CoreValve device. This study uses one year patient level
data (PLD) from the ADVANCE registry to assess the long term cost- effectiveness of
CoreValve for the treatment of aortic stenosis (AS).
Methods: ADVANCE enrolled 1015 patients; 996 underwent attempted CoreValve
implantation. A Markov model was developed in Microsoft Excel for CoreValve vs.
MM. Key information for the MM arm (mortality, adverse events, health related
quality of life (HRQoL) were sourced from PARTNER B (3 year follow-up). Where
possible, all information for the CoreValve arm was taken from the ADVANCE study,
and the PLD was also used to stratify mortality by STS risk score. CoreValve related
stroke events were included in the model design. Unit costs were taken from national
databases. HRQoL in both arms was incorporated via utility decrements applied to
age-speciﬁc EQ-5D population norms to generate quality adjusted life years (QALYs).
Results are reported as means and 95% conﬁdence intervals. Extensive deterministic
and probabilistic sensitivity analyses were conducted. Costs and beneﬁts were dis-
counted at 3.5% per annum.
Results: In the ADVANCE dataset there were 42 stroke events through 1 year; 12
occurred after 30 days post-procedure. Over a 10 year time period the model generated
survival estimates of 5.76 and 1.63 years for CoreValve and MM, respectively. The
incremental cost-effectiveness ratio (ICER) is £14,255 (£11,844 to £17,190) per
QALY gained. CoreValve is more costly than MM but nonetheless a cost-effective
treatment. The ICER for CoreValve patients in the highest STS category is £16,891
(£13,565 to £21,855) per QALY gained. The model was insensitive to changes in the
approach to model utility beneﬁts, baseline survival curves and hospitalization rates.
Conclusions: From a UK perspective, CoreValve is a cost-effective treatment for
inoperable patients with severe AS patients compared to medical management.
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Background: Standard procedure for transcatheter aortic valve implantation (TAVI)
using the Sapien stent valve (Edwards Lifesciences Corporation, Irvine, California)
incorporates balloon dilatation (+BAV) prior to valve deployment. Earlier studies
have shown limited effect of BAV. Echocardiography may underestimate the actual
area of the valve compared to the surgical impression. By combining this knowledge
with thoroughly imaging the valve and coronary arteries with TOE and CT prior to
intervention we decided to implant the Sapien stent valve without BAV (-BAV).
Methods: This non-randomized study includes 160 consecutive patients from
September 2008 to April 2013. +BAV was performed in the ﬁrst 96 patients and
–BAV in the following 64 patients. Parameters regarding procedural success, valve
function and 30 day mortality are compared.
Results:Mean age in both groups were 80 years, 57% were women in +BAV vs 47%
in -BAV. Euroscore 1 and STS in + BAV were 17.5 and 5.6, in -BAV 18.7 and 7.0.
Aortic stenoses were degenerative in 91% in both groups, the rest valve-in-valve or
post-radiation. For further results see table. We had good valve positioning in all
patients, no coronary artery occlusion, no problems crossing the valve in –BAV
patients and no variation between transapical or transfemoral approach.
Conclusions: TAVI with the Sapien valve without predilatation is feasible, with
good valve positioning and function, and no increased associated complications.1, 2013 j TCT Abstracts/POSTER/Aortic Valve Disease and Treatment
